AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00626951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: Extraglottic airway devices
Study NCT00626951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Study NCT01066910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for childhood obesity
Description: Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
Study NCT01066910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral treatment for childhood obesity
Description: Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
Study NCT03209765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp reminder
Description: An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
Study NCT05490771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05490771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05490771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study NCT00970177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study NCT05490771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous Oxide
Description: A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Study NCT01736020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05115578 — intervention group
Intervention type: DRUG
Intervention: Remifentanil 1 MG Injection [Ultiva]
Description: Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
Study NCT01021332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
Description: oral
Study NCT05115578 — intervention group
Intervention type: DRUG
Intervention: Midazolam 1 MG/ML Prefilled Syringe
Description: Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
Study NCT05115578 — intervention group
Intervention type: DRUG
Intervention: Saline solution
Description: Group III Control
Study NCT01021332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Description: oral
Study NCT05115578 — intervention group
Intervention type: DEVICE
Intervention: Algometry
Description: The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
Study NCT01069627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg intravenously on day 1 of every 3 week cycle
Study NCT01069627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fotemustine
Description: 100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
Study NCT01959386 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
Study NCT04771884 — intervention group
Intervention type: DRUG
Intervention: meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid
Description: The use of antimicrobial agents depends on the clinical practice
Study NCT02396251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA experimental
Study NCT02396251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA experimental
Study NCT02396251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA comparator
Study NCT03740867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
Study NCT02210468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIC-CF, 4 cc
Study NCT02210468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIC-CF, 2 cc
Study NCT02210468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Saline
Description: Placebo Comparator: Saline
Study NCT00521612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
Study NCT00521612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane
Description: Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
Study NCT02867085 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
Study NCT03041532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal retroflexion
Description: The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
Study NCT03041532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontal view
Description: The investigator explore twice right colon with frontal viewing
Study NCT03041532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontal view
Description: The investigator explore twice right colon with frontal viewing
Study NCT04415047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Trilogy Heart Valve System
Description: TAVR with JenaValve Trilogy Heart Valve System
Study NCT04692857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra inguinal fascia iliaca block
Description: injection of 30,40 or 50 ml of 0.2 ropivacaine .
Study NCT03436316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154
Description: SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
Study NCT01685216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: lyophilized powder, intravenous infusion, units, Every other week (EOW)
Study NCT01142908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist CVD
Description: clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
Study NCT04573309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered orally as tablets.
Study NCT02874287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Study NCT02874287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Tablets
Description: Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Study NCT04646824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT01264198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Supervised Resistance Training
Study NCT01264198 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance Training
Description: Supervised Resistance Training
Study NCT03770793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung-sono guided
Description: The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible.
Study NCT03033030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound examination
Study NCT04171401 — intervention group
Intervention type: OTHER
Intervention: In-patient stroke rehabilitation.
Description: An in-patient multi-disciplinary stroke rehabilitation program was performed.
Study NCT03815409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with partial weight unload
Description: 10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
Study NCT03815409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional PT rehabilitation treatment
Description: Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
Study NCT01991886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm Precision Flow
Description: Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
Study NCT03980756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 20mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03980756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03980756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 40mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03980756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT04660435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thymidine kinase activity
Description: DiviTum® assay determines the enzymatic activity of TK in serum samples
Study NCT01459315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
Study NCT03748472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous gavage feeding
Description: Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
Study NCT00498186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)
Study NCT03748472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bolus feeding
Description: Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
Study NCT01267656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricating and Rewetting Drops
Description: Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
Study NCT01267656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Blink Contacts Lubricant Eye Drops
Description: Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
Study NCT00859183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
Study NCT00859183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
Study NCT00859183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral
Study NCT04510376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Article
Description: Omeza Collagen Matrix
Study NCT04510376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: 1.0 mg/mL Histamine Base
Study NCT04510376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: Aqueous Negative Control
Study NCT04485910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single step media
Description: Usage of single step media in embryo culture
Study NCT04485910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequential media
Description: Usage of sequential media in embryo culture
Study NCT02196974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryobiopsy
Study NCT00674427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD28 Activated T cells
Description: Subjects who are not in CR will receive one infusion of high dose aDLI
Study NCT00674427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD28 Activated T cells
Description: Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
Study NCT02192073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapectoral Biceps tenodesis
Study NCT02192073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subpectoral biceps tenodesis
Study NCT02337738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets
Study NCT02337738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 0.5mg
Description: TVP-1012 0.5mg Tablets
Study NCT02337738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study NCT00237185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
Study NCT03496571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
Study NCT03496571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00596297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
Study NCT04403776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib MR 11 mg
Description: Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
Study NCT00596297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: 4 weeks after baseline
Study NCT04152044 — intervention group
Intervention type: OTHER
Intervention: Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy
Description: Patinets undergoing surgery
Study NCT04403776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib IR 5 mg
Description: Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.